top of page

Top selling immunology drugs | Top 10 immunology drugs by revenues | iPharmaCenter


TOP IMMUNOLOGY DRUGS BY REVENUES IN 2022

Humira (Adalimumab):

In the realm of immunology drugs, one name stands out as a global success story - Humira. This medication, administered via injection, is an inhibitor of tumour necrosis factor-alpha (TNF-alpha), a pivotal protein in the body's inflammatory response.


What truly sets Humira apart is its extensive list of approved indications. With a resounding stamp of approval from the medical community, Humira has been entrusted to combat a broad spectrum of autoimmune diseases. From the persistent grip of rheumatoid arthritis to the challenges posed by Crohn's disease, psoriatic arthritis, plaque psoriasis, and the discomfort of ankylosing spondylitis, Humira has offered solace to patients worldwide.


AbbVie continually expanded Humira's scope by seeking new indications and innovating delivery methods. AbbVie implemented multiple patient assistance programs to drive the uptake of Humira. These initiatives opened doors for patients facing financial constraints, ensuring that even those without insurance coverage could obtain this life-changing medication.


Dupixent (Dupilumab):

Dupixent, a revolutionary monoclonal antibody, relieves those suffering from severe allergic and inflammatory conditions. Dupixent was developed through the collaborative efforts of Regeneron Pharmaceuticals and Sanofi, zeroes in on interleukin-4 receptor alpha (IL-4Ra), a critical player in inflammation. Dupixent has emerged as a beacon of hope for individuals battling conditions like eczema, asthma, and chronic rhinosinusitis with nasal polyposis.


With the recently announced positive data in COPD, it was expected that Dupixent could touch peak revenues of $ 20 billion.

Stelara (Ustekinumab):

Developed by Janssen Pharmaceuticals, Stelara targets specific cytokines - interleukin-12 (IL-12) and interleukin-23 (IL-23) - implicated in the fiery storm of inflammation. With approvals for conditions ranging from psoriasis to Crohn's disease and ulcerative colitis, Stelara has stood as a steadfast companion in the journey to relief.


Stelara, introduced to the market in 2009, has held its position as J&J's leading pharmaceutical product since 2019, achieving sales of $9.7 billion in 2022. As its patents are set to expire this year, this paves the way for more affordable biosimilars to enter the market

Johnson & Johnson settled a lawsuit with Amgen, based on which Amgen will not have the opportunity to market its Stelara biosimilar before January 2025.

Skyrizi (Risankizumab):

Developed by AbbVie, Skyrizi is designed to combat interleukin-23 (IL-23), a cytokine at the heart of inflammation. With its approval for psoriasis and psoriatic arthritis, Skyrizi is offering the promise of clearer, more comfortable days.

Enbrel (Etanercept):

A joint effort between Amgen and Pfizer, this TNF inhibitor has stood as a good protector against inflammation. It relieves individuals with rheumatoid arthritis, psoriasis, psoriatic arthritis, and ankylosing spondylitis.


Cosentyx (Secukinumab):

Marketed by Novartis, Cosentyx acts on interleukin-17A (IL-17A), a central figure in inflammation. Cosentyx was approved for conditions like psoriasis, psoriatic arthritis, and ankylosing spondylitis, offering new hope to those seeking relief.

Orencia (Abatacept):

Marketed by Bristol Myers Squibb, this medication modulates T-cell activation, curbing the autoimmune response. With approvals for rheumatoid arthritis and juvenile idiopathic arthritis, Orencia offers an alternative path to managing these conditions and enhancing patients' quality of life.

Actemra (Tocilizumab):

Actemra targets interleukin-6 (IL-6), a crucial player in inflammation. Its approval for conditions like rheumatoid arthritis, giant cell arteritis, and systemic juvenile idiopathic arthritis has ushered in a new era of treatment possibilities.

Tremfya (Guselkumab):

Developed by Janssen Pharmaceuticals, Tremfya is a monoclonal antibody designed to target interleukin-23 (IL-23), a cytokine central to autoimmune disorders. Tremfya's approval for psoriasis has offered patients a path to clearer skin and a brighter future.

Rinvoq (Upadacitinib):

Rinvoq is a Janus kinase (JAK) inhibitor that disrupts the signalling pathways driving inflammation. With approvals for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and more, Rinvoq empowers patients to regain control over their lives.

0 comments

Comentários


bottom of page